Background: Increasing evidence supporting the role of immune checkpoint blockade in
cancer management has been bolstered by recent reports demonstrating significant and …

A well-known tumor suppressor, p21, acts paradoxically by promoting tumor growth in some
cellular conditions. These conflicting functions have been demonstrated in association with …

Background The majority of urothelial cancers (UC) harbor alterations in retinoblastoma
(Rb) pathway genes that can lead to loss of Rb tumour suppressor function. Palbociclib is an …

We investigated the correspondence between transcriptome and exome alterations in
canine bladder cancer and the correspondence between these alterations and cancer …

Mutations in the P53 pathway are a hallmark of human cancer. The identification of
pathways upon which p53-deficient cells depend could reveal therapeutic targets that may …

Cancer is a genetic and complex disorder, resulting from several events associated with
onset, development, and metastasis. Tumor suppressors and oncogenes are among the …

BACKGROUND Biopsies from patients with high‐risk (HR) non–muscle‐invasive urothelial
carcinoma (NMIUC), especially flat urothelial carcinoma in situ, frequently contain scant …

Genomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in
bladder cancer patient-derived xenografts - PMC Back to Top Skip to main content NIH NLM …

Background Urachal cancer is a rare cancer that develops in the urachus. Because of its
rarity, standard treatment therapies for urachal cancer are not established, and …

The overall goal of translational oncology is to identify molecular alterations indicative of
cancer or of responsiveness to specific therapeutic regimens. While next-generation …